{"schema_version":"secwatch.filing_event.v1","accession":"0001570562-24-000078","form_type":"8-K","ticker":"EOLS","cik":"0001570562","company_name":"Evolus, Inc.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.015038+00:00","generated_at":"2026-06-02T18:21:22.382753+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Evolus Q1 revenue up 42% YoY to $59.3M; on track for non-GAAP profitability in Q4 2024","bullets":["Net revenue $59.3M (+42% YoY); gross margin 68.3%; non-GAAP loss from ops $0.9M, narrowing from Q4 2023's $3.7M.","Reaffirms FY2024 revenue guidance of $255-265M; expects non-GAAP profitability in Q4 2024 and full-year 2025.","FDA submission for Evolysse dermal fillers within 90 days; expanding into Australia and Spain with Nuceiva.","Added 700+ new customer accounts; reorder rate ~70%; Evolus Rewards members ~825,000."],"urls":{"canonical":"https://secwatch.observer/filing/0001570562-24-000078","json":"https://secwatch.observer/filing/0001570562-24-000078.json","markdown":"https://secwatch.observer/filing/0001570562-24-000078.md","text":"https://secwatch.observer/filing/0001570562-24-000078.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1570562/000157056224000078/0001570562-24-000078-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1570562/000157056224000078/eols-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T18:21:22.382753+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"334d4230bfcc129601d8a97b63d3d01877af513d","claim":"Evolus, Inc. reported the first quarter ended March 31, 2024 results: revenue $59.3 million. Guidance reaffirmed.","evidence_excerpt":"Total net revenues for the first quarter of 2024 increased 42% to $59.3 million from $41.7 million in the first quarter of 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056224000078/0001570562-24-000078-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Revenue","value":"$59.3 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}